PTGX - Protagonist Therapeutics, Inc.
About Protagonist Therapeutics, Inc. (https://www.protagonist-inc.com)
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Dinesh V. Patel | Chief Executive Officer, President, Secretary & Director | 1957 | $1,414,292 USD |
| Arturo Molina FACP | Chief Medical Officer | 1959 | $949,992 USD |
| Asif Ali | Executive Vice President & Chief Financial Officer | 1974 | $826,242 USD |
| Abha Bommireddi | Executive Vice President & Chief of Staff | – | – |
| Ashok Bhandari | EVP & Chief Discovery Officer | 1964 | – |
| Carena Spivey | Executive VP & Chief Human Resources Officer | – | – |
| Carter J. King | Executive Vice President of Business Development | 1971 | – |
| Matthew Gosling | Executive Vice President and Chief Legal & Business Officer | 1971 | – |
| Newman Yeilding | Executive Vice President, Chief Scientific Officer | – | – |
| Samuel R. Saks | Clinical Development Advisor | 1955 | – |
| Venkat Thalladi | EVP & Chief Technical Officer | – | – |